Publications by authors named "R Fasce"
Background: Vaccine effectiveness against SARS-CoV-2 infection has been somewhat limited due to the widespread dissemination of the Omicron variant, its subvariants, and the immune response dynamics of the naturally infected with the virus.
Methods: Twelve subjects between 3-17 years old (yo), vaccinated with two doses of CoronaVac, were followed and diagnosed as breakthrough cases starting 14 days after receiving the second dose. Total IgGs against different SARS-CoV-2 proteins and the neutralizing capacity of these antibodies after infection were measured in plasma.
Article Synopsis
- Clade 2.3.4.4b highly pathogenic avian influenza A(H5N1) viruses have led to large outbreaks in birds and have occasionally infected mammals, raising concerns about their potential to spread to humans.
- A recent study investigated a novel strain from Chile that caused severe illness in a human; tests in ferrets showed it could cause serious disease and transmit through direct contact but not through airborne means.
- The findings suggest that while this strain poses a high risk, it would need further mutations to become airborne and potentially lead to a pandemic, highlighting the importance of ongoing surveillance of these viruses in mammals and humans.
H5N1 highly pathogenic avian influenza viruses (HPAIV) emerged in wild birds in Chile in December 2022 and spilled over into poultry, marine mammals, and one human. Between December 9, 2022 - March 14, 2023, a coordinated government/academic response detected HPAIV by real-time RT-PCR in 8.5% (412/4735) of samples from 23 avian and 3 mammal orders.
View Article and Find Full Text PDFHighlights: Here we present the first human case of Influenza A H5N1 infection in Chile, and the fifth worldwide in 2023. The patient is a 53-year-old man who lives in the north region of Chile, near the seashore. The Chilean sample was subtyped in the clade 2.
View Article and Find Full Text PDFObjectives: This study estimated the 2022 end-of-season influenza vaccine effectiveness (VE) against severe acute respiratory illness (SARI) hospitalization in Chile, Paraguay, and Uruguay.
Methods: We pooled surveillance data from SARI cases in 18 sentinel surveillance hospitals in Chile (n = 9), Paraguay (n = 2), and Uruguay (n = 7) from March 16-November 30, 2022. VE was estimated using a test-negative design and logistic regression models adjusted for country, age, sex, presence of ≥1 comorbidity, and week of illness onset.